92 related articles for article (PubMed ID: 9816911)
1. [Involvement of tau protein kinase in amyloid-beta-induced neurodegeneration].
Ishiguro K
Rinsho Byori; 1998 Oct; 46(10):1003-7. PubMed ID: 9816911
[TBL] [Abstract][Full Text] [Related]
2. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.
Imahori K; Uchida T
J Biochem; 1997 Feb; 121(2):179-88. PubMed ID: 9089387
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
4. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
5. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
6. GSK-3 inhibitors for Alzheimer's disease.
Avila J; Hernández F
Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
[TBL] [Abstract][Full Text] [Related]
7. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
8. Increased tau phosphorylation at the Ser396 epitope after amyloid beta-exposure in organotypic cultures.
Johansson S; Jämsä A; Vasänge M; Winblad B; Luthman J; Cowburn RF
Neuroreport; 2006 Jun; 17(9):907-11. PubMed ID: 16738486
[TBL] [Abstract][Full Text] [Related]
9. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
van de Nes JA; Nafe R; Schlote W
Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathology of Alzheimer neurofibrillary degeneration.
Iqbal K; Alonso A; Gong C; Khatoon S; Kudo T; Singh T; Grundke-Iqbal I
Acta Neurobiol Exp (Wars); 1993; 53(1):325-35. PubMed ID: 8317268
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
12. Inverse and distinct modulation of tau-dependent neurodegeneration by presenilin 1 and amyloid-beta in cultured cortical neurons: evidence that tau phosphorylation is the limiting factor in amyloid-beta-induced cell death.
Leschik J; Welzel A; Weissmann C; Eckert A; Brandt R
J Neurochem; 2007 Jun; 101(5):1303-15. PubMed ID: 17298384
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
14. Isoaspartate formation and neurodegeneration in Alzheimer's disease.
Shimizu T; Watanabe A; Ogawara M; Mori H; Shirasawa T
Arch Biochem Biophys; 2000 Sep; 381(2):225-34. PubMed ID: 11032409
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease.
Pérez M; Morán MA; Ferrer I; Avila J; Gómez-Ramos P
Acta Neuropathol; 2008 Oct; 116(4):409-18. PubMed ID: 18679696
[TBL] [Abstract][Full Text] [Related]
16. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice.
Ribé EM; Pérez M; Puig B; Gich I; Lim F; Cuadrado M; Sesma T; Catena S; Sánchez B; Nieto M; Gómez-Ramos P; Morán MA; Cabodevilla F; Samaranch L; Ortiz L; Pérez A; Ferrer I; Avila J; Gómez-Isla T
Neurobiol Dis; 2005 Dec; 20(3):814-22. PubMed ID: 16125396
[TBL] [Abstract][Full Text] [Related]
17. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation.
Koistinaho M; Kettunen MI; Goldsteins G; Keinänen R; Salminen A; Ort M; Bures J; Liu D; Kauppinen RA; Higgins LS; Koistinaho J
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1610-5. PubMed ID: 11818564
[TBL] [Abstract][Full Text] [Related]
18. Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice.
Christensen DZ; Kraus SL; Flohr A; Cotel MC; Wirths O; Bayer TA
Acta Neuropathol; 2008 Dec; 116(6):647-55. PubMed ID: 18974993
[TBL] [Abstract][Full Text] [Related]
19. The involvement of the ubiquitin system in Alzheimer's disease (review).
Pallares-Trujillo J; Lopez-Soriano FJ; Argilés JM
Int J Mol Med; 1998 Jul; 2(1):3-15. PubMed ID: 9854137
[TBL] [Abstract][Full Text] [Related]
20. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
Pei JJ; Sjögren M; Winblad B
Curr Opin Psychiatry; 2008 Nov; 21(6):555-61. PubMed ID: 18852562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
